CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort study.

IF 5.8 2区 医学 Q1 Medicine
Noriyuki Enomoto, Shogo Nakai, Shusuke Yazawa, Yasutaka Mochizuka, Atsuki Fukada, Yuko Tanaka, Hyogo Naoi, Yusuke Inoue, Hideki Yasui, Masato Karayama, Yuzo Suzuki, Hironao Hozumi, Kazuki Furuhashi, Mikio Toyoshima, Masato Kono, Shiro Imokawa, Masato Fujii, Taisuke Akamatsu, Naoki Koshimizu, Koshi Yokomura, Hiroyuki Matsuda, Yusuke Kaida, Yutaro Nakamura, Masahiro Shirai, Kazutaka Mori, Masafumi Masuda, Tomoyuki Fujisawa, Naoki Inui, Hiroaki Sugiura, Hiromitsu Sumikawa, Masashi Kitani, Kazuhiro Tabata, Noriyoshi Ogawa, Takafumi Suda
{"title":"CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort study.","authors":"Noriyuki Enomoto, Shogo Nakai, Shusuke Yazawa, Yasutaka Mochizuka, Atsuki Fukada, Yuko Tanaka, Hyogo Naoi, Yusuke Inoue, Hideki Yasui, Masato Karayama, Yuzo Suzuki, Hironao Hozumi, Kazuki Furuhashi, Mikio Toyoshima, Masato Kono, Shiro Imokawa, Masato Fujii, Taisuke Akamatsu, Naoki Koshimizu, Koshi Yokomura, Hiroyuki Matsuda, Yusuke Kaida, Yutaro Nakamura, Masahiro Shirai, Kazutaka Mori, Masafumi Masuda, Tomoyuki Fujisawa, Naoki Inui, Hiroaki Sugiura, Hiromitsu Sumikawa, Masashi Kitani, Kazuhiro Tabata, Noriyoshi Ogawa, Takafumi Suda","doi":"10.1186/s12931-024-02982-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Interstitial pneumonia with autoimmune features (IPAF), which does not meet any of the criteria for connective tissue diseases (CTD), has been attracting an attention in patients with idiopathic interstitial pneumonia (IIP). However, the biomarkers that reflect the clinical course of these patients have not been fully elucidated.</p><p><strong>Objective: </strong>To identify useful serum biomarkers reflecting CTD-related features and favorable prognoses in patients with IIP.</p><p><strong>Methods: </strong>This was a post hoc analysis of a prospective and multicenter cohort study between 2015 and 2020. Newly diagnosed patients with IIP were consecutively enrolled, and 74 autoimmune features and autoantibodies were comprehensively checked during IIP diagnosis. Serum levels of CXCL10, CXCL1, CCL2, BAFF, angiopoietin-2, and leptin were evaluated at the time of IIP diagnosis.</p><p><strong>Results: </strong>Two hundred twenty-two patients (159 men and 63 women) with IIP were enrolled. The median observation duration was 36 months. The median age was 71 years old, and median %forced vital capacity (FVC) was 84.1% at the time of IIP diagnosis. The proportion of patients who met the classification criteria for IPAF was 11.7%. In patients with high serum CXCL10, changes in both %FVC and %diffusion lung capacity for carbon monoxide at one year were significantly higher than those in patients with low CXCL10 (p = 0.014 and p = 0.009, respectively), whereas these changes were not significant for other chemokines and cytokines. High CXCL10 levels were associated with acute/subacute onset (p < 0.001) and the diagnosis of nonspecific interstitial pneumonia with organizing pneumonia overlap (p = 0.003). High CXCL10 levels were related to a higher classification of IPAF (relative risk for IPAF was 3.320, 95%CI: 1.571-7.019, p = 0.003) and lower classification of progressive pulmonary fibrosis (PPF; relative risk for PPF was 0.309, 95%CI: 0.100-0.953, p = 0.027) compared to those with low CXCL10. Finally, survival was higher in patients with IPF and high CXCL10 (p = 0.044), and high CXCL10 was a significant prognostic factor in multivariate Cox proportional hazards models (hazard ratio 0.368, p = 0.005).</p><p><strong>Conclusions: </strong>High serum levels of CXCL10 are associated with CTD-related features, the favorable clinical course, and survival in patients with IIP, especially IPF.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":49131,"journal":{"name":"Respiratory Research","volume":null,"pages":null},"PeriodicalIF":5.8000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439282/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12931-024-02982-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Interstitial pneumonia with autoimmune features (IPAF), which does not meet any of the criteria for connective tissue diseases (CTD), has been attracting an attention in patients with idiopathic interstitial pneumonia (IIP). However, the biomarkers that reflect the clinical course of these patients have not been fully elucidated.

Objective: To identify useful serum biomarkers reflecting CTD-related features and favorable prognoses in patients with IIP.

Methods: This was a post hoc analysis of a prospective and multicenter cohort study between 2015 and 2020. Newly diagnosed patients with IIP were consecutively enrolled, and 74 autoimmune features and autoantibodies were comprehensively checked during IIP diagnosis. Serum levels of CXCL10, CXCL1, CCL2, BAFF, angiopoietin-2, and leptin were evaluated at the time of IIP diagnosis.

Results: Two hundred twenty-two patients (159 men and 63 women) with IIP were enrolled. The median observation duration was 36 months. The median age was 71 years old, and median %forced vital capacity (FVC) was 84.1% at the time of IIP diagnosis. The proportion of patients who met the classification criteria for IPAF was 11.7%. In patients with high serum CXCL10, changes in both %FVC and %diffusion lung capacity for carbon monoxide at one year were significantly higher than those in patients with low CXCL10 (p = 0.014 and p = 0.009, respectively), whereas these changes were not significant for other chemokines and cytokines. High CXCL10 levels were associated with acute/subacute onset (p < 0.001) and the diagnosis of nonspecific interstitial pneumonia with organizing pneumonia overlap (p = 0.003). High CXCL10 levels were related to a higher classification of IPAF (relative risk for IPAF was 3.320, 95%CI: 1.571-7.019, p = 0.003) and lower classification of progressive pulmonary fibrosis (PPF; relative risk for PPF was 0.309, 95%CI: 0.100-0.953, p = 0.027) compared to those with low CXCL10. Finally, survival was higher in patients with IPF and high CXCL10 (p = 0.044), and high CXCL10 was a significant prognostic factor in multivariate Cox proportional hazards models (hazard ratio 0.368, p = 0.005).

Conclusions: High serum levels of CXCL10 are associated with CTD-related features, the favorable clinical course, and survival in patients with IIP, especially IPF.

Clinical trial number: Not applicable.

CXCL10可预测IIP患者的自身免疫特征和良好的临床过程:一项前瞻性多中心队列研究的事后分析。
背景:在特发性间质性肺炎(IIP)患者中,不符合结缔组织病(CTD)标准的自身免疫性间质性肺炎(IPAF)一直备受关注。然而,反映这些患者临床病程的生物标志物尚未完全阐明:目的:确定反映特发性间质性肺炎患者 CTD 相关特征和良好预后的有用血清生物标志物:这是对2015年至2020年间一项前瞻性多中心队列研究的事后分析。新诊断的IIP患者连续入组,在IIP诊断期间全面检查了74种自身免疫特征和自身抗体。在诊断 IIP 时评估血清中 CXCL10、CXCL1、CCL2、BAFF、血管生成素-2 和瘦素的水平:共纳入 222 名 IIP 患者(男性 159 人,女性 63 人)。中位观察期为 36 个月。中位年龄为 71 岁,诊断 IIP 时的中位肺活量(FVC)为 84.1%。符合 IPAF 分类标准的患者比例为 11.7%。在血清 CXCL10 水平高的患者中,一年后一氧化碳的肺活量百分比和扩散肺活量百分比的变化均显著高于血清 CXCL10 水平低的患者(分别为 p = 0.014 和 p = 0.009),而其他趋化因子和细胞因子的变化则不显著。高水平的 CXCL10 与急性/亚急性发病有关(p 结论:高水平的 CXCL10 与急性/亚急性发病有关:高水平的血清 CXCL10 与 CTD 相关特征、良好的临床过程以及 IIP(尤其是 IPF)患者的生存率有关:临床试验编号:不适用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Respiratory Research
Respiratory Research RESPIRATORY SYSTEM-
CiteScore
9.70
自引率
1.70%
发文量
314
审稿时长
4-8 weeks
期刊介绍: Respiratory Research publishes high-quality clinical and basic research, review and commentary articles on all aspects of respiratory medicine and related diseases. As the leading fully open access journal in the field, Respiratory Research provides an essential resource for pulmonologists, allergists, immunologists and other physicians, researchers, healthcare workers and medical students with worldwide dissemination of articles resulting in high visibility and generating international discussion. Topics of specific interest include asthma, chronic obstructive pulmonary disease, cystic fibrosis, genetics, infectious diseases, interstitial lung diseases, lung development, lung tumors, occupational and environmental factors, pulmonary circulation, pulmonary pharmacology and therapeutics, respiratory immunology, respiratory physiology, and sleep-related respiratory problems.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信